A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Personalis, Inc. (NASDAQ:PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can accurately identify triple negative breast cancer (TNBC) patients at high risk of ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association ...